Advantages and limits of ADAMTS13 testing in the prognostic assessment of thrombotic thrombocytopenic purpura

Pier Mannuccio Mannucci, Massimo Franchini

Research output: Contribution to journalArticle

Abstract

Thrombotic thrombocytopenic purpura (TTP) is a rare but severe disease characterized by mechanical hemolytic anemia and consumptive thrombocytopenia leading to disseminated microvascular thrombosis that causes signs and symptoms of organ ischemia and functional damage. After the elucidation of the pathophysiology of TTP, thanks to the demonstration of the congenital or acquired (autoimmune) plasma deficiency of the von Willebrand factor cleaving metalloprotease A Disintegrin And Metalloprotease with Thrombo. Spondin 1 repeats (ADAMTS13), a number of laboratory assays for measuring ADAMTS13 and related autoantibodies have been developed. Current knowledge on the diagnostic and prognostic value of ADAMTS13 and anti-ADAMTS13 assays is summarized in this review.

Original languageEnglish
JournalPresse medicale (Paris, France : 1983)
Volume41
Issue number3 PART 2
DOIs
Publication statusPublished - Mar 2012

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Advantages and limits of ADAMTS13 testing in the prognostic assessment of thrombotic thrombocytopenic purpura'. Together they form a unique fingerprint.

  • Cite this